Back to top
more

TrovaGene, Inc. (TROV)

(Delayed Data from NSDQ)

$3.62 USD

3.62
312,960

+0.03 (0.84%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Trovagene's Onvansertib Shows Response in Phase Ib AML Study

by Zacks Equity Research

Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.

Trovagene (TROV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Trovagene (TROV) delivered earnings and revenue surprises of -33.33% and 12.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    TrovaGene Enters Oversold Territor

    by Zacks Equity Research

    TrovaGene Enters Oversold Territor

      TrovaGene (TROV) Enters Oversold Territory

      by Zacks Equity Research

      TrovaGene, Inc. (TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

        TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4

        by Zacks Equity Research

        TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.

          TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy?

          by Zacks Equity Research

          TrovaGene, Inc. (TROV) has been struggling lately, but the selling pressure may be coming to an end soon

            Trovagene to Focus More on Liquid Biopsy Testing Market

            by Zacks Equity Research

            Trovagene, Inc. (TROV), recently announced that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market.

              TrovaGene Inks Contract with Boreal Genomics, Stock Down

              by Zacks Equity Research

              TrovaGene Inc. (TROV), a molecular diagnostic company, recently announced the signing of a long-term Supply and Distribution Agreement with Boreal Genomics.